The interferon-free combination of the protease inhibitor ABT-@ with ritonavir ( ABT-@ / r ) and the NS@A inhibitor ombitasvir ( also known as ABT-@ ) plus the nonnucleoside polymerase inhibitor dasabuvir ( also known as ABT-@ ) and ribavirin has shown efficacy against the hepatitis C virus ( HCV ) in patients with HCV genotype @ infection .